With an approval based on two pivotal Phase III studies, Dupixent is now the first-ever biologic indicated for treating COPD.

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

The drug BMF-219 works by increasing, preserving and reactivating patients’ own healthy insulin-producing cells. Read more at ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

A groundbreaking new drug to treat schizophrenia called Cobenfy, owned by pharmaceutical firm Bristol Myers Squibb, has been ...

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...

Even after a hurricane’s immediate flooding threat goes away, residents could face a host of potential health problems from the water — and what it leaves behind.

Zymeworks is awaiting key regulatory decisions for zanidatamab, with potential EU and China approvals following. Read more ...

In this opinion piece, Richard Owen of the American Peanut Council argues for negotiating new trade deals and ...

Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure, the personal consumption expenditures ...

The increase is nearly double last year’s 7.7. percent raise and driven by higher market costs this year, the Office of ...

Leerink Partners Biopharma Private Company Connect Format: 1x1 Investor Meetings Date/Time: Tuesday, October 22 and Wednesday, October 23 Location: Virtual ...